This clinical trial is focused on studying persistent atrial fibrillation, a condition where the heart beats irregularly and often rapidly for extended periods. The study aims to evaluate the effectiveness of two different doses of a medication called amiodarone hydrochloride, which is used to help maintain a normal heart rhythm after a procedure known as cardioversion. Cardioversion is a treatment that helps restore a regular heart rhythm in people with certain types of abnormal heartbeats.
The purpose of the study is to compare the ability of a standard dose (200 mg per day) and a reduced dose (100 mg per day) of amiodarone hydrochloride to maintain a normal heart rhythm for 12 months after cardioversion in patients with persistent atrial fibrillation. Participants in the study will be randomly assigned to receive either the standard dose or the reduced dose of the medication. Some participants may receive a placebo, which looks like the medication but does not contain the active ingredient.
Throughout the study, participants will be monitored for any recurrence of irregular heartbeats and for any side effects that may occur. The study will also look at how the body processes the medication and whether genetic factors affect its effectiveness and safety. The trial is expected to continue until June 2028, with recruitment starting in November 2024.
Spain 
